Mustang Bio Announces Participation in Upcoming Scientific Meetings
06 juil. 2023 08h00 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
15 juin 2023 16h01 HE
|
Mustang Bio, Inc.
10 out of 20 patients remain in complete remission for more than a year 95% overall response rate (ORR) and 80% complete response (CR) rate across all patients; 100% ORR and 91% CR with higher dose...
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
12 juin 2023 08h00 HE
|
Mustang Bio, Inc.
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months ...
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
18 mai 2023 08h03 HE
|
Mustang Bio, Inc.
uBriGene (Boston) Biosciences to acquire Mustang Bio’s Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support...
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
12 mai 2023 16h05 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
11 mai 2023 16h03 HE
|
Mustang Bio, Inc.
Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May ...
Mustang Bio Announces Reverse Stock Split
03 avr. 2023 12h15 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
29 mars 2023 16h15 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium
28 mars 2023 08h30 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
17 janv. 2023 08h15 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...